Chronic Intradialytic Exercise : a Cardioprotective Role (EX-CHRODIAL)

November 28, 2023 updated by: University of Avignon

Chronic Intradialytic Exercise: a Cardioprotective Role

The main objective is to assess the effects of chronic intradialytic physical exercise on myocardial remodelling and regional function.

Study Overview

Status

Completed

Detailed Description

Background: Hemodialysis patients have a mortality rate 50 times higher than in the general population, and the cause remains cardiovascular in more than half of the cases. A deleterious morphological and functional cardiac remodelling is well established in these patients, the causes of which are both the presence of factors specific to renal disease (hemodynamic and non-hemodynamic) and co-morbidities (diabetes, hypertension, etc. .) but also to the hemodialysis (HD) procedure itself, due to the sudden hemodynamic changes it imposes, leading to repeated episodes of intradialytic hypotension (HID) and myocardial stunning. The latter are now documented as direct contributors to the increased mortality observed in HD patients compared to the general population. The introduction of intradialytic physical exercise in the therapeutic program of HD patient is now recommended and practised routinely in many countries, in Scandinavia in particular. Several meta-analyses have clearly established its safety. The beneficial role of chronic intradialytic exercise in improving dialysis efficiency, mental health and quality of life, as well as the inflammatory status of HD patients is also clearly demonstrated. Chronic intradialytic exercise is also associated with improvements in overall fitness level, a parameter closely linked to cardiovascular mortality. Applied acutely during dialysis, it could play a cardioprotective role (e.g; limiting myocardial stunning), allowing haemodynamic and cardiac functional stabilization during HD. However, to our knowledge, no study to date has investigated the long-term effects of intradialytic exercise on remodelling and overall and regional heart function.

Aims: The main objective is to assess the effects of chronic intradialytic physical exercise on myocardial remodelling and regional function. The secondary objectives are to evaluate the effect of acute intradialytic exercise on myocardial stunning as well as the effect of chronic physical exercise on macro and microcirculatory vascular function, inflammation, physical fitness and health-related quality of life.

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gard
      • Nîmes, Gard, France, 30029
        • Centre Hemodialyse AIDER sante
    • Vaucluse
      • Avignon, Vaucluse, France, 84000
        • ATIR

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 79 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • No medical contraindication to physical activity
  • Life expectancy greater than 6 months
  • Patients on haemodialysis for more than 3 months

Exclusion Criteria:

  • Pregnancy

    • Valvular heart disease,
    • Unstable coronary artery disease
    • Arteriopathy obliterating of the lower limbs stage III and IV
    • Musculoskeletal problems
    • Severe respiratory disease
    • BMI> 35
    • Pacemaker, cardiac stimulation and automatic implantable defibrillator
    • Heart transplant
    • Uncontrolled arterial hypertension
    • Ejection fraction <45%

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HD-EX (patient with intradialytic exercise)
will be enrolled in a 16 week intradilatytic exercise program.
1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning
No Intervention: HD (patients with standard HD)
patients with standard hemodialysis (e.g. without exercise).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in myocardial longitudinal deformations
Time Frame: Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Myocardial longitudinal linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode.
Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Changes in myocardial longitudinal deformations
Time Frame: Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).
Myocardial longitudinal linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode.
Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).
Changes in myocardial circumferential deformations
Time Frame: Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Myocardial circumferential linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode.
Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Changes in myocardial circumferential deformations
Time Frame: Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).
Myocardial circumferential linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode.
Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).
Changes in left ventricular torsion
Time Frame: Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Left ventricular torsion (in degree) will be assessed by high-resolution echocardiography in deformation imaging mode.
Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Changes in left ventricular torsion
Time Frame: Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).
Left ventricular torsion (in degree) will be assessed by high-resolution echocardiography in deformation imaging mode.
Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in arterial rigidity
Time Frame: before (week 0) and after (week 17) an exercise training program of 16 weeks
Measurement of pulse wave velocity (m/s) by photo-plethysmography at rest before dialysis.
before (week 0) and after (week 17) an exercise training program of 16 weeks
Changes in Physical fitness
Time Frame: before (week 0) and after (week 17) an exercise training program of 16 weeks
The six-minute walking test (meters); maximal isometric force (newtons) during a knee-extension test and handgrip test using a dynamometer.
before (week 0) and after (week 17) an exercise training program of 16 weeks
Health-related Quality of life
Time Frame: before (week 0) and after (week 17) an exercise training program of 16 weeks
The 36-Item Short Form Health Survey questionnaire. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.
before (week 0) and after (week 17) an exercise training program of 16 weeks
Changes in carotid intimal-media wall thickness
Time Frame: before (week 0) and after (week 17) an exercise training program of 16 weeks
The intimal plus media wall thickness (mm) of the right carotid artery will be measured using high-resolution echography.
before (week 0) and after (week 17) an exercise training program of 16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Philippe Obert, Pr., Avignon University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 13, 2020

Primary Completion (Actual)

May 14, 2023

Study Completion (Actual)

September 30, 2023

Study Registration Dates

First Submitted

December 14, 2020

First Submitted That Met QC Criteria

January 4, 2021

First Posted (Actual)

January 6, 2021

Study Record Updates

Last Update Posted (Actual)

November 29, 2023

Last Update Submitted That Met QC Criteria

November 28, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Renal Failure

Clinical Trials on chronic phase

Subscribe